T4	Pharmacological_substance 161 170	imiquimod
N1000 	Reference T4 MeSH:C056493	imiquimod
T7	Pharmacological_substance 181 219	necrosis factor (TNF)-alpha inhibitors
T8	Disorder 285 309	non-melanoma skin cancer
T9	Disorder 340 349	psoriasis
N1 	Reference T9 UMLS:C0033860	psoriasis
T10	Pharmacological_substance 477 486	imiquimod
N1001 	Reference T10 MeSH:C056493	imiquimod
T11	Pharmacological_substance 505 523	TNF-alpha blockers
T14	Pharmacological_substance 690 699	imiquimod
N1002 	Reference T14 MeSH:C056493	imiquimod
T15	Pharmacological_substance 718 728	infliximab
N1003 	Reference T15 MeSH:D000069285	infliximab
T16	Disorder 748 757	psoriasis
N2 	Reference T16 UMLS:C0033860	psoriasis
T17	Pharmacological_substance 878 898	TNF-alpha inhibitors
T20	Pharmacological_substance 964 973	imiquimod
N1004 	Reference T20 MeSH:C056493	imiquimod
T21	Pharmacological_substance 1157 1175	TNF-alpha blockers
T24	Pharmacological_substance 1180 1189	imiquimod
N1005 	Reference T24 MeSH:C056493	imiquimod
T1	Pharmacological_substance 12 21	imiquimod
N1006 	Reference T1 MeSH:C056493	imiquimod
T3	Disorder 311 315	NMSC
T19	Disorder 534 566	cutaneous inflammatory reactions
T22	Disorder 388 414	application site reactions
N3 	Reference T22 UMLS:C0151505	application site reactions
T25	Disorder 416 420	ASRs
N4 	Reference T25 UMLS:C0151505	ASRs
T27	Disorder 643 647	ASRs
N5 	Reference T27 UMLS:C0151505	ASRs
T28	Disorder 670 674	NMSC
T23	Disorder 954 958	ASRs
N6 	Reference T23 UMLS:C0151505	ASRs
T33	Speculation_cue 913 927	susceptibility
T37	Speculation_cue 1085 1096	possibility
T39	Speculation_cue 492 501	potential
T2	Disorder 22 48	application site reactions
N7 	Reference T2 UMLS:C0151505	application site reactions
T30	Manner_cue 371 387	mild to moderate
T40	Manner_cue 626 632	severe
T6	Combination 171 174	and
T12	Combination 700 717	in the context of
T31	Combination 959 963	with
T34	Combination 1176 1179	and
